Cross-talk between the interleukin-6 and prostaglandin E2 signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-κB (RANK) ligand/RANK system

Endocrinology

Volumn 146, Issue 4, 2005, Pages 1991-1998

  Liu, Xin Hua ^a   Kirschenbaum, Alexander ^a   Yao, Shen ^a   Levine, Alice C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2;

ARTICLE; BONE DISEASE; BONE REMODELING; CELL DIFFERENTIATION; CELL GROWTH; COCULTURE; MOLECULAR INTERACTION; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; CARRIER PROTEINS; CELL LINE; DINOPROSTONE; GLYCOPROTEINS; INTERLEUKIN-6; MEMBRANE GLYCOPROTEINS; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 15444362701     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-1167     Document Type: Article

References (55)

1. Heymann D, Rousselle AV 2000 Gp130 cytokine family and bone cells. Cytokine 12:1455-1468
2. Fohr B, Dunstan CR, Seibel MJ 2003 Markers of bone remodeling in metastatic bone disease. J Clin Endcrinol Metab 88:5059-5075
3. Brandstrom H, Bjorkman T, Ljunggren O 2001 Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 280:831-835
4. Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurakai T, Tamura M, Takahashi N, Suda T 1996 Osteoclast function is activated by osteoblastic cells through mechanism involving cell-to-cell contact. Endocrinology 137:2187-2190
5. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for OPG/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602
6. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K 1998 RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400
7. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ, et al 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
8. Ohlsson C, Bengtsson BA, Isakasson OG, Andreassen TT, Slootweg MC 1998 Growth hormone and bone. Endocr Rev 19:55-79
9. Okada Y, Lorenzo JA, Freeman AM, Tomita M, Morham SG, Raisz LG, Pilbeam CC 2000 Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105:823-832
10. 2 in young rats increase the osteogenic capacity of bone marrow. Bone 20:521-526
11. 2 on bone mass in rat long bones and calvariae. J Endocrinol 156:51-57
12. Forwood MR 1996 Inducible cyclooxygenase-2 mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 11:1688-1693
13. Zhang X, Schwarz EM, Young DA, Puzas J, Rosier RN, O'Keefe RJ 2002 Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109:1405-1415
14. Ono K, Akatsu T, Murakami T, Kitamura R, Yamamoto M, Rokutanda M, Nagata N, Kugai N 2002 involvement of cyclooxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 17:774-781
15. Zhang X, Morham SG, Langenbach R, Young DA, Xing L, Boyce BF, Puzas EJ, Rosier RN, O'Keefe RJ, Schwarz EM 2001 Evidence for a direct role of cyclooxygenase-2 in implant wear debris induced osteolysis. J Bone Miner Res 16:660-669
16. 2 in rat bone marrow cultures is mediated via EP4 receptor subtype. Am J Physiol 276:E376-E383
17. 2 on gene expression in primary osteoblastic cell from prostaglandin receptor knockout mice. Bone 30:567-573
18. 4-knockout mice. J Biol Chem 275:19819-19823
19. 2 receptor impairs osteoclastogenesis in vitro. Endocrinology 141: 2054-2061
20. Kishimoto T 1989 The biology of interleukin-6. Blood 74:1-10
21. Legrand-Poels S, Schoonbroodt S, Piette J 2000 Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line: Biochem J 349:765-773
22. Otsuka T, Thacker JD, Hogge DE 1991 The effects of interleukin-6 and interleukin-3 on early hematopoietic events in long-term cultures of human bone marrow. Exp Hematol 19:1042-1048
23. Kuehl WM, Bergsagel PL 2002 Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 1:175-187
24. 2 synthesis and cyclooxygenase-2 activity are regulated both by a nitric oxide-dependent and -independent mechanism in rat osteoblast in vitro. J Biol Chem 274:1776-1782
25. Taga T, Kishimoto T 1997 Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797-819
26. Sims NA, Jenkins BJ, Ouinn JMW, Nakamura A, Glatt M, Gillepie MT, Ernst M, Martin TJ 2004 Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. J Clin Invest 113:379-389
27. Hirano T, Ishihara K, Hibi M 2000 Roles of Stat-3 in mediating the cell growth, differentiation and survival signals relayed through the interleukin-6 family of cytokine receptors. Oncogene 19:2548-2556
28. Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Finflay DM, Martin TJ, Hirota H, Kishimoto T, Suda T 1995 Interleukin-6 induction of osteoclast differentiation dependent on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 182:1461-1468
29. 2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest 110:651-658
30. Hong SH, Ondrey FC, Avis IM, Chen Z, Loukinova E, Cavanaugh Jr PF, Waes CV, Mulshine JL 2000 Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine interleukin-6: a general role for inflammation? FASEB J 14:1499-1507
31. 2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun 290:249-255
32. 2 and calcemic hormones of interleukin-6 in stromal/osteoblastic cells. Biochem Biophys Res Commun 270:1080-1085
33. 2: cross-talk regulation by protein kinase C. Bone 22:355-360
34. Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, Levine AC 1999 Up-regulation of vascular endothelial growth factor by cobalt-induced hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastases 17:687-694
35. 2 induces hypoxia-inducible factor-1α stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277: 50081-50086
36. Jones MK, Wang H, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS 1999 Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and uncle healing. Nat Med 5:1418-1423
37. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL 2000 The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141:4768-4776
38. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC 2003 RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101:2094-2098
39. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H 2000 Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-κB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 275:768-775
40. Zhang J, Dai J, Qi Y, Lin D-L, Smith P, Strayhorn C, Mizokami A, Fu A, Weatman J, Keller ET 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244
41. Tai H, Miyaura C, Pilbeam CC, Tamura T, Ohsugi Y, Koishihara Y, Kubodera N, Kawaguchi H, Raisz LG, Suda T 1997 Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoclast formation. Endocrinology 138:2372-2379
42. Origuchi T, Migita K, Nakashima T, Honda S, Yamasaki S, Hida A, Kawakami A, Aoyagi T, Kawabe Y, Eguchi K 2000 Regulation of cyclooxygenase-2 expression in human osteoblastic cells by N-acetylcysteine. J Lab Clin Med 136:390-394
43. Jilka RL, Hangoc G, Girasole G, Passen G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC 1992 Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257:88-91
44. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Single FR 1992 Interleukin-6, a potential autocrine/paracrine factor in Paget's disease of the bone. J Clin Invest 89:46-52
45. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M, Kishimoto T 1998 Interleukin-6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 95:8222-8226
46. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Oshugi Y, Kumaki K, Taga T, Kishimoto T, Suda T 1993 Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA 90:11924-11928
47. 3 on interleukin-6-dependent osteoclast-like cell formation in mouse bone marrow cell culture. Bone 22:341-346
48. Sandhu JS, Gorczynski RM, Waddell J, Nguyen H, Squires J, Waddell J, Boynton EL, Hozumi N 1999 Effect of interleukin-6 secreted by engineered human stromal cells on osteoclasts in human bone. Bone 24:217-227
49. 3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures. Endocrinology 138:4567-4571
50. Greenfield EM, Shaw SM, Gornik SA, Banks MA 1995 Adenyl cyclase and interleukin-6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest 96:1238-1244
51. 4 receptor activation. Proc Natl Acad Sci USA 99:4580-4585
52. 4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res 15:218-227
53. 2. Mol Pharmacol 60:36-41
54. 2 in periarticular osteoporosis of postmenopausal woman with rheumatoid arthritis. J Bone Miner Metab 19:89-96
55. Ni Z, Lou W, Leman ES, Gao AC 2000 Inhibition of constitutively activated Stat-3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60:1225-1228